Distinct Bile Acid Signature in Parkinson's Disease With Mild Cognitive Impairment.
Front Neurol
; 13: 897867, 2022.
Article
in En
| MEDLINE
| ID: mdl-35860484
ABSTRACT
Backgrounds Bile acid (BA) plays a crucial role in various neurodegenerative diseases, including Parkinson's disease (PD). However, no clinical evidence supports BA's potential role in patients with PD with mild cognitive impairment (PD-MCI). Objectives:
This study aimed at investigating the differential BA profile between patients with PD-MCI and those with normal cognitive function (PD-NC).Methods:
Ultra-high performance liquid chromatography-MS/MS was applied for BA quantitation. After between-group differences of the BA profile were addressed, orthogonal projections to latent structures-discriminant analysis (OPLS-DA) and the area under the receiver-operating-characteristic curve (AUC-ROC) were implemented for further verification.Results:
Lower levels of chenodeoxycholic acid (CDCA), cholic acid (CA), and ursodeoxycholic acid (UDCA) were significantly associated with PD-MCI (p < 0.01 for both; VIP ≈ 2.67, 1.66, and 1.26, respectively). AUC-ROC were 78.1, 74.2, and 74.5% for CDCA, CA, and UDCA, respectively.Conclusion:
CA, CDCA, and UDCA might be distinct BA signatures for patients with PD-MCI.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Front Neurol
Year:
2022
Document type:
Article
Affiliation country: